(-0.71%) 5 071.00 points
(-0.61%) 38 445 points
(-1.10%) 17 470 points
(0.60%) $83.31
(-0.24%) $1.649
(0.01%) $2 338.60
(0.12%) $27.38
(0.04%) $916.20
(-0.03%) $0.934
(-0.14%) $10.97
(-0.17%) $0.801
(-0.38%) $91.97
-1.01% ¥ 3 710.00
Live Chart Being Loaded With Signals
Hisamitsu Pharmaceutical Co., Inc. manufactures and sells pharmaceuticals, quasi-drugs, and medical devices in Japan. The company provides external pain relieving drugs under the SALONPAS, NOBINOBI, SALONSIP, AIR, SALONPAS, and FEITAS; and BUTENALOCK, a remedy for athlete's foot, as well as ALLEGRA FX, a sinus medication for allergies...
Stats | |
---|---|
Today's Volume | 203 900 |
Average Volume | 167 018 |
Market Cap | 281.01B |
EPS | ¥0 ( 2024-04-10 ) |
Next earnings date | ( ¥0 ) 2024-07-11 |
Last Dividend | ¥42.50 ( 2023-08-30 ) |
Next Dividend | ¥0 ( N/A ) |
P/E | 20.12 |
ATR14 | ¥1.320 (0.04%) |
Volume Correlation
Hisamitsu Pharmaceutical Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Hisamitsu Pharmaceutical Correlation - Currency/Commodity
Hisamitsu Pharmaceutical Financials
Annual | 2023 |
Revenue: | ¥141.71B |
Gross Profit: | ¥78.97B (55.73 %) |
EPS: | ¥181.62 |
Q4 | 2023 |
Revenue: | ¥38.88B |
Gross Profit: | ¥20.37B (52.40 %) |
EPS: | ¥24.53 |
Q3 | 2023 |
Revenue: | ¥35.85B |
Gross Profit: | ¥19.95B (55.66 %) |
EPS: | ¥48.52 |
Q2 | 2023 |
Revenue: | ¥34.88B |
Gross Profit: | ¥19.93B (57.13 %) |
EPS: | ¥56.25 |
Financial Reports:
No articles found.
Hisamitsu Pharmaceutical Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
¥0.250 (N/A) |
¥0 (N/A) |
¥0.250 (N/A) |
¥0 (N/A) |
¥42.50 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | ¥7.00 | 2001-02-23 |
Last Dividend | ¥42.50 | 2023-08-30 |
Next Dividend | ¥0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 42 | -- |
Total Paid Out | ¥1 175.50 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.73 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 4.60 | |
Div. Directional Score | 7.69 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
8316.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
7716.T | Ex Dividend Knight | 2023-12-28 | Semi-Annually | 0 | 0.00% | |
6869.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
6240.T | Ex Dividend Junior | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
4966.T | Ex Dividend Knight | 2024-03-28 | Annually | 0 | 0.00% | |
4151.T | Ex Dividend Knight | 2023-12-28 | Semi-Annually | 0 | 0.00% | |
3355.T | Ex Dividend Junior | 2023-12-28 | Annually | 0 | 0.00% | |
2429.T | Ex Dividend Junior | 2023-12-28 | Annually | 0 | 0.00% | |
9366.T | Ex Dividend Junior | 2024-03-28 | Annually | 0 | 0.00% | |
8057.T | Ex Dividend Knight | 2024-07-18 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0986 | 1.500 | 8.03 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0425 | 1.200 | 8.58 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0524 | 1.500 | -0.529 | -0.793 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 4.22 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 3.66 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 2.45 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.00455 | -1.500 | 9.92 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 731.56 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 96.01 | 2.00 | 10.00 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 96.01 | 2.00 | 10.00 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.00565 | -1.500 | 9.98 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.557 | 1.000 | 4.05 | 4.05 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0929 | 1.000 | -0.142 | -0.142 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 4.86 | 1.000 | 10.00 | 10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.431 | 0.800 | -0.460 | -0.368 | [0.5 - 2] |
Total Score | 10.77 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 20.22 | 1.000 | 8.06 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0524 | 2.50 | -0.340 | -0.793 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 96.01 | 2.00 | 10.00 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 2.28 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 96.01 | 2.00 | 10.00 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.890 | 1.500 | 7.40 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.0514 | 1.000 | -1.216 | 0 | [0.1 - 0.5] |
Total Score | 4.60 |
Hisamitsu Pharmaceutical
Hisamitsu Pharmaceutical Co., Inc. manufactures and sells pharmaceuticals, quasi-drugs, and medical devices in Japan. The company provides external pain relieving drugs under the SALONPAS, NOBINOBI, SALONSIP, AIR, SALONPAS, and FEITAS; and BUTENALOCK, a remedy for athlete's foot, as well as ALLEGRA FX, a sinus medication for allergies. It also manufactures and sells quasi-drugs and cosmetics; MOHRUS TAPE and MOHRUS PAP XR, transdermal analgesic anti-inflammatory drug; patches for female hormone, asthma treatment, and treatment for overactive bladders. In addition, the company manufactures and sells drugs under MOHRUS TAPE, MOHRUS PAP XR, FENTOS Tapes, NEOXY Tapes, Abstral, ALLESAGA Tapes, HARUROPI Tapes, and MENOAID Combipatch. Further, it provides HFT-290, a transdermal patch for cancer pain. The company sells its products in the United States and Asia. Hisamitsu Pharmaceutical Co., Inc. was founded in 1847 and is headquartered in Tosu, Japan.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators